📢 New Publication from Pharmidex!
March 24, 2026
We are pleased to share our latest publication:
“Magnetic field-induced drug delivery from magnetic microporous nanocomposites through magnetic nanoparticles heating or motion”, published in the journal
Materials & Design.
This work explores innovative approaches to magnetically triggered drug delivery, leveraging the unique properties of magnetic nanoparticles to enable controlled release through heating and motion mechanisms. These advances have the potential to open new avenues in targeted therapies and precision medicine.
We would like to sincerely thank our collaborators for their valuable contributions to this research:
-CRCT Université de Toulouse Inserm U1037 CNR
-Laboratoire de Physique et Chimie des Nano-Objets (LPCNO) CNRS-UPS-INSA
-Centro Singular de Investigación en Química Biológica y Materiales Moleculares (CIQUS)
We are proud to contribute to cutting-edge research at the interface of nanotechnology and drug delivery and we look forward to continuing collaborations that drive innovation in drug discovery and development.
🔗 Read the full article:
https://www.sciencedirect.com/science/article/pii/S0264127526003084?via%3Dihub
#DrugDelivery #Nanotechnology #DrugDiscovery #MaterialsScience #Innovation #Collaboration #Pharmidex
We are delighted to announce and congratulate Ash Alavijeh on his appointment as Chief Operating Officer at Pharmidex . Ash has been an integral part of Pharmidex’s journey, bringing strong leadership, strategic vision and a deep commitment to advancing our capabilities in drug discovery and development. In his new role as COO, he will play a key part in driving operational excellence and supporting the continued growth of the company. This appointment reflects both Ash’s contributions to date and our confidence in his leadership as we continue to expand and evolve. Please join us in congratulating Ash on this well-deserved achievement.
Asthma affects over 260 million people worldwide and remains a significant unmet medical need. At Pharmidex , we are proud to support the development of next-generation respiratory therapies through: In vivo respiratory disease models Whole Body Plethysmography (WBP) for functional readouts Integrated PK/PD and bioanalysis Our focus is simple: generate high-quality data that enables confident decision-making and accelerates progress for patients. Because behind every dataset is a patient waiting to breathe easier.
Early-stage innovators based in Scotland have access to a significant opportunity to advance their programs toward ProofOfConcept, with an additional £2.85M fund from the Scottish Government aimed at supporting early development and enabling further investment. 🗓️ Deadline: 8th May At Pharmidex , we work alongside our partners to generate robust, translational data that supports confident decision-making across early discovery and preclinical development. Our capabilities include: TargetExpression ModeOfActionStudies TargetEngagement HitIdentification ADME and PK profiling If you are preparing an application and require scientific input or timely quotations, we would be pleased to support your programme. 🔗 https://lnkd.in/eZ6vVjgN
